Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Predicted Market Size Trajectory For The Acute Renal Failure (ARF) Market From 2025 To 2034?
The acute renal failure (arf) market has shown robust expansion in recent years. It is projected to increase from $6.09 billion in 2024 to $6.6 billion by 2025, at a compound annual growth rate (CAGR) of 8.2%. This historical growth can be attributed to several factors including a rising aging population, the growing incidence of sepsis, improved diagnostic capabilities, various government healthcare initiatives, and an increase in cases involving nephrotoxic medication.
The acute renal failure (arf) market size is anticipated to experience substantial growth over the next few years. It is projected to expand to $9.02 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 8.1%. The expansion during the forecast period is attributable to the increasing availability of home-based dialysis solutions, the emergence of new markets, the development of renal biomarkers, research and development for new therapeutic drugs, and a rising demand for non-invasive diagnostics. Major trends expected in the forecast period include advancements in continuous renal replacement therapy (CRRT), the application of 3D bioprinting for renal tissue, the introduction of wearable biosensors, the development of next-generation dialysis machines, and innovations in nanotechnology-driven drug delivery.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21083&type=smp
What Are The Key Drivers Of Growth In The Acute Renal Failure (ARF) Market?
The acute renal failure (ARF) market is anticipated to expand due to the rising occurrence of chronic kidney diseases. Chronic kidney disease (CKD) is defined as a persistent condition in which the kidneys suffer damage, hindering their ability to effectively filter blood. This growing prevalence of chronic kidney disease (CKD) can be attributed to a global increase in diabetes, hypertension, obesity, an aging demographic, and lifestyle choices. Acute renal failure, which involves an abrupt decline in kidney function, can considerably initiate or worsen chronic kidney disease. This occurs by inflicting permanent harm on kidney tissues, reducing their filtration capacity, and elevating the likelihood of ongoing, protracted kidney impairment if not adequately treated. For example, a report released by Kidney Research UK, a UK-based non-profit organization, in June 2023, indicated that around 7.2 million individuals in the UK are currently afflicted with chronic kidney disease, accounting for more than 10% of the population. Among these, 3.25 million have reached advanced stages of the condition, while another 3.9 million are in its initial phases. Projections suggest that by 2033, the population affected by chronic kidney disease will increase to 7.61 million. Consequently, the growing occurrence of chronic kidney diseases is a key factor propelling the expansion of the acute renal failure (ARF) market.
What Are The Leading Segments Analyzed In The Acute Renal Failure (ARF) Market?
The acute renal failure (arf)market covered in this report is segmented –
1) By Disease Type: Prerenal Acute Renal Failure; Renal Acute Renal Failure; Postrenal Acute Renal Failure
2) By Drug Type: Diuretics; Vasopressors; Erythropoiesis-Stimulating Agents (ESAS); Phosphate Binders; Calcium and Vitamin D Supplements; Antibiotics; Others Drugs
3) By Route of Administration: Oral; Intravenous
4) By Diagnosis: Computed Tomography (CT) Scan; Kidney Biopsy; Ultrasound
5) By End-Users: Clinics; Hospitals; Home Healthcare; Others End-Users
Subsegments:
1) By Prerenal Acute Renal Failure: Hypovolemia; Decreased Cardiac Output; Renal Artery Stenosis
2) By Renal Acute Renal Failure: Acute Tubular Necrosis; Glomerulonephritis; Interstitial Nephritis
3) By Postrenal Acute Renal Failure: Obstructive Uropathy; Bladder Outlet Obstruction; Kidney Stones
Which Competitive Trends Are Defining The Acute Renal Failure (ARF) Market Structure?
Leading companies active in the acute renal failure (ARF) market are prioritizing the acquisition of regulatory authorizations for their drugs, aiming to broaden their reach and solidify their standing in the treatment of severe acute kidney injury (AKI). These regulatory approvals represent official consent from governmental or oversight bodies, allowing for the marketing and public distribution of medications, medical devices, or therapeutic procedures. For instance, in February 2024, CalciMedica, a US-based clinical-stage biopharmaceutical company, obtained FDA approval for an IND application to initiate a Phase 2 trial of Auxora. This trial seeks to evaluate Auxora’s effectiveness in treating severe acute kidney injury (AKI) when associated with acute hypoxemic respiratory failure (AHRF), a condition known for its high mortality rate. The KOURAGE trial, a randomized, double-blind, placebo-controlled study, is designed to enroll approximately 150 patients who have Stage 2 and 3 acute kidney injury (AKI) along with acute hypoxemic respiratory failure (AHRF). It will assess Auxora’s efficacy, administered over five daily doses, by examining the number of days patients survive without requiring ventilators or dialysis for up to 30 days following treatment.
Which Leading Companies Dominate The Acute Renal Failure (ARF) Market Share?
Major companies operating in the acute renal failure (ARF) market are Pfizer Inc., Novartis AG, LG Chem Ltd., Medtronic plc, Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Corporation, Baxter International Inc., Astellas Pharma Inc., Syensqo, Dr. Reddy’s Laboratories Limited, Zydus Lifesciences Limited, NIKKISO Co., Ltd., Quark Pharmaceuticals Inc., NIPRO Corporation, Alloksys Life Sciences B.V., AM-Pharma B.V., Sentien Biotechnologies, MediBeacon LLC, Angion Biomedica Corp., Atox Bio Ltd.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/acute-renal-failure-arf-global-market-report
How Do Regional Market Performances Compare Within The Acute Renal Failure (ARF) Industry?
North America was the largest region in the acute renal failure (ARF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute renal failure (ARF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Acute Renal Failure (ARF) Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21083&type=smp
Browse Through More Reports Similar to the Global Acute Renal Failure (ARF) Market 2025, By The Business Research Company
Renal Biomarkers Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report
End Stage Renal Disease Esrd Drug Global Market Report 2025
Hepatorenal Syndrome Treatment Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model